结直肠癌中DPYD基因变异的研究进展  

Research progress of DPYD gene variation in colorectal cancer

作　　者：陶昀璐(综述)[1] 王振军(审校)[1] 

机构地区：[1]首都医科大学附属北京朝阳医院普外科,100020

出　　处：《肿瘤研究与临床》2014年第3期206-209,共4页Cancer Research and Clinic

摘　　要：5-氟尿嘧啶（5-Fu）目前已成为结直肠癌辅助化疗的首选药物,80％以上的5-Fu都是由二氢嘧啶脱氢酶（DPD）代谢降解的.当编码DPD的基因即DPYD基因突变导致DPD部分或完全缺陷时,可引起5-Fu不良反应,包括腹泻、口腔炎、手足综合征及神经毒性等.文章就DPYD基因变异的研究背景、研究现状及对临床的指导意义作一综述.5-fluorouracil （5-Fu） as the most common adjuvant chemotherapy has been widely used for patients with colorectal cancer. As reported dihydropyrimidine dehydrogenase （DPD） has been known as an initial rate-limiting enzyme to catalyze approximately 80 % of administered dose of 5-Fu. However, patients with a partial or complete DPD deficiency because of the mutation of DPYD gene may suffer from diarrhea, stomatitis, hand-foot syndrome or neurotoxicity and even death. In this article, the application of DPYD gene screening in patients with colorectal cancer of current status and recent clinical application are reviewed.

关 键 词：结直肠肿瘤 基因 DPYD 基因变异 药物疗法 

分 类 号：R512.62[医药卫生—内科学]